Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.1
3.0
Journals
Antibodies
Special Issues
Antiphospholipid Antibodies
share announcement

Antiphospholipid Antibodies

A special issue of Antibodies (ISSN 2073-4468). This special issue belongs to the section "Antibody-Based Therapeutics".

Deadline for manuscript submissions: closed (30 June 2024) | Viewed by 9671

Special Issue Editors

Dr. Md Asiful Islam

E-Mail Website
Guest Editor
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
Interests: autoimmunity; antiphospholipid syndrome; antiphospholipid antibodies; autoimmune diseases
Prof. Dr. Przemysław Kotyla

E-Mail Website
Guest Editor
Department of Internal Medicine, Rheumatology and Clinical Immunology, Faculty in Katowice, Medical University of Silesia, Katowice, Poland
Interests: systemic lupus erythematosus; rheumatic diseases; autoimmunity; clinical rheumatology; autoimmune disorders
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleauges,

Antiphospholipid antibodies (aPLs) are those that are directed against phospholipids—the phosphorus-containing fats that make up our cell membranes. Certain blood proteins interact with phospholipids and the immune complexes produced when proteins and phospholipids interact. The lupus anticoagulant (LA), anticardiolipin antibody (aCL) and anti-beta-2-glycoprotein 1 (anti-β2GPI) antibodies are the three aPLs that are most frequently mentioned which are also known as the classic aPLs. There are a number of non-classic aPLs such as antiphosphatidylserine, antiphosphatidylinositol, antiphosphatidicacid, antiphosphatidylethanolamine, antiphosphatidylglycerol, anti-annexin V or antiprothrombin antibodies. To date, strong evidence indicates the causative factor of some of the aPLs in developing thrombotic events and pregnancy complications (i.e., recurrent miscarriage). In addition, aPLs have been found to be significantly present in patients exhibiting autoimmune or rheumatic diseases like antiphospholipid syndrome, systemic lupus erythematosus or Behcet's disease, cancers (i.e., solid or haematologic malignancies), and neurologic conditions like migraine, dementia or epilepsy. This may indicate that the role of aPLs goes far beyond the biomarker role only and may be directly involved in the pathogenesis of various autoimmune disorders. An example of this is that during the COVID-19 pandemic, significantly higher titres of aPLs were observed in patients with COVID-19.

In this Special Issue, we would be inviting researchers to submit their original research or review articles on the aPLs as a mediator or diagnostic tool for different diseases or conditions. We especially appreciate papers on aPLs as potential novel biomarkers in different diseases, aPLs-mediated pathogenesis in different conditions, novel laboratory testing and optimisation of aPLs detection, and clinical, epidemiological or basic-science-oriented investigations on aPLs.

Dr. Md Asiful Islam
Prof. Dr. Przemysław Kotyla
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antiphospholipid antibodies
  • lupus anticoagulant
  • anticardiolipin antibody
  • anti-β2-glycoprotein I antibody
  • antiphospholipid syndrome
  • autoimmunity
  • autoimmune diseases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

16 pages, 1179 KiB  
Review
Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria
by Lucas Jacobs, Nader Wauters, Yahya Lablad, Johann Morelle and Maxime Taghavi
Antibodies 2024, 13(1), 21; https://doi.org/10.3390/antib13010021 - 12 Mar 2024
Cited by 5 | Viewed by 6169
Abstract
Catastrophic antiphospholipid syndrome (CAPS) is a rare and life-threatening condition characterized by the persistence of antiphospholipid antibodies and occurrence of multiple vascular occlusive events. CAPS currently remains a diagnostic challenge and requires urgent treatment. The diagnosis of CAPS is made difficult by classification [...] Read more.
Catastrophic antiphospholipid syndrome (CAPS) is a rare and life-threatening condition characterized by the persistence of antiphospholipid antibodies and occurrence of multiple vascular occlusive events. CAPS currently remains a diagnostic challenge and requires urgent treatment. The diagnosis of CAPS is made difficult by classification criteria used as diagnostic criteria in clinical practice, knowledge derived from retrospective data and case reports, confounding clinical and biological features, and its rapid onset and mortality. The absence of prospective studies of CAPS limits the strength of evidence for guideline treatment protocols. This comprehensive review summarizes the current understanding of the disease, and discusses how the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria impact the definition and therapeutic management of CAPS, which is considered the most severe form of APS. The correct integration of 2023 ACR/EULAR APS classification criteria is poised to facilitate CAPS diagnosis, particularly in critical situations, offering a promising avenue for improved outcomes. Full article
(This article belongs to the Special Issue Antiphospholipid Antibodies)
►▼ Show Figures

Figure 1

Other

Jump to: Review

15 pages, 2793 KiB  
Systematic Review
Vitamin D Status in Patients with Primary Antiphospholipid Syndrome (PAPS): A Systematic Review and Meta-Analysis
by Md Asiful Islam, Saleh Ahmed, Shabiha Sultana, Sayeda Sadia Alam, Tareq Hossan, Wesam Gouda, Faisal Alsaqabi, Rosline Hassan and Przemysław J. Kotyla
Antibodies 2024, 13(1), 22; https://doi.org/10.3390/antib13010022 - 13 Mar 2024
Viewed by 2699
Abstract
Primary antiphospholipid syndrome (PAPS) is a systemic autoimmune disorder, characterised by consistently high levels of antiphospholipid antibodies, thrombosis, and/or pregnancy morbidity. Due to various suspected causes, deficient or insufficient levels of vitamin D in the serum have been reported in patients with PAPS; [...] Read more.
Primary antiphospholipid syndrome (PAPS) is a systemic autoimmune disorder, characterised by consistently high levels of antiphospholipid antibodies, thrombosis, and/or pregnancy morbidity. Due to various suspected causes, deficient or insufficient levels of vitamin D in the serum have been reported in patients with PAPS; however, the reports have been sporadic and inconclusive. This systematic review and meta-analysis aimed to comprehensively evaluate the serum vitamin D levels in patients with PAPS compared to controls. A protocol was registered in PROSPERO (Registration No. CRD42019132128) and a systematic literature search was conducted through Google Scholar, PubMed, Web of Science, Scopus, and ScienceDirect databases without restricting language and year. Pooled prevalence, mean difference (MD), and odds ratio (OR) along with 95% confidence intervals (CI) were determined by using a random effects model. Study quality was assessed by the Joana Brigg’s Institute (JBI) protocol and publication bias was evaluated by a trim and fill funnel plot, Begg’s, and Egger’s tests. The pooled prevalence of vitamin D deficiency and insufficiency was found to be 32.2% [95% CI: 16.3–48.2] and 61.5% [95% CI: 40.2–82.8], respectively. Serum levels of vitamin D were considerably lower in the PAPS patients compared to controls (MD: −5.75, 95% CI: −9.73 to −1.77; p = 0.005). Multiple sensitivity analyses showed that the results remained statistically significant, demonstrating the robustness of this meta-analysis. No significant publication bias was detected in determining the MD of serum vitamin D levels in PAPS and controls. In conclusion, PAPS patients had greater rates of vitamin D deficiency or insufficiency, higher frequency of thrombosis, and lower serum vitamin D levels than healthy individuals. Full article
(This article belongs to the Special Issue Antiphospholipid Antibodies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop